clinical trial · NCT07295717
A Study to Evaluate ALN-4285 in Adult Healthy Volunteers
Healthy VolunteersALN-4285Placebo
brief summary
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4285 in healthy volunteers * characterize the single-dose pharmacokinetics (PK) of ALN-4285
started
Dec 12, 2025
primary completion
Dec 29, 2026
completion
Mar 23, 2027
last updated
May 14, 2026
official title
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered ALN-4285 in Adult Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol